WO2004103375A1 - 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 - Google Patents
末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 Download PDFInfo
- Publication number
- WO2004103375A1 WO2004103375A1 PCT/JP2004/006539 JP2004006539W WO2004103375A1 WO 2004103375 A1 WO2004103375 A1 WO 2004103375A1 JP 2004006539 W JP2004006539 W JP 2004006539W WO 2004103375 A1 WO2004103375 A1 WO 2004103375A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infusion
- intravenous administration
- preparation
- peripheral intravenous
- vitamin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 title claims abstract description 43
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 24
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 10
- 230000000087 stabilizing effect Effects 0.000 title claims description 9
- 229960003495 thiamine Drugs 0.000 claims abstract description 42
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 39
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 39
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 39
- 150000001413 amino acids Chemical class 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 16
- 239000008103 glucose Substances 0.000 claims abstract description 16
- 238000004448 titration Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001802 infusion Methods 0.000 claims description 159
- 229940024606 amino acid Drugs 0.000 claims description 21
- 235000001014 amino acid Nutrition 0.000 claims description 21
- 239000003792 electrolyte Substances 0.000 claims description 18
- 239000003978 infusion fluid Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 11
- 239000007785 strong electrolyte Substances 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 238000000638 solvent extraction Methods 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 239000004201 L-cysteine Substances 0.000 claims description 3
- 235000013878 L-cysteine Nutrition 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 229930195722 L-methionine Natural products 0.000 claims description 3
- 229930182821 L-proline Natural products 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 125000003047 N-acetyl group Chemical group 0.000 claims description 3
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000004888 barrier function Effects 0.000 claims description 3
- 229920002457 flexible plastic Polymers 0.000 claims description 3
- 229960002989 glutamic acid Drugs 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- 229960004452 methionine Drugs 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229960002429 proline Drugs 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 230000006641 stabilisation Effects 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 239000004158 L-cystine Substances 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 238000005192 partition Methods 0.000 abstract description 8
- 238000004891 communication Methods 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- 229960003975 potassium Drugs 0.000 description 8
- -1 fructose and maltose Chemical class 0.000 description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000001540 sodium lactate Substances 0.000 description 6
- 235000011088 sodium lactate Nutrition 0.000 description 6
- 229940005581 sodium lactate Drugs 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 239000001103 potassium chloride Substances 0.000 description 5
- 235000011164 potassium chloride Nutrition 0.000 description 5
- 229960002816 potassium chloride Drugs 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000003139 buffering effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- DGYBMJWDHSYLBQ-UHFFFAOYSA-M P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[K+] Chemical compound P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[K+] DGYBMJWDHSYLBQ-UHFFFAOYSA-M 0.000 description 1
- BSZBUWZYEDZOFY-UHFFFAOYSA-M P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[Na+] Chemical compound P(=O)([O-])(O)O.C(C(O)CO)(=O)O.[Na+] BSZBUWZYEDZOFY-UHFFFAOYSA-M 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012476 oxidizable substance Substances 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- SYGDCNJESIQXKS-UHFFFAOYSA-M potassium;2,3-dihydroxypropanoate Chemical compound [K+].OCC(O)C([O-])=O SYGDCNJESIQXKS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to an infusion preparation for peripheral venous administration containing vitamin B1 stably, and a method for stabilizing vitamin B1.
- infusion therapy in which an infusion is administered through a vein has been widely performed in order to replenish all the nutrients necessary for life support to a patient who is difficult to orally supply nutrition.
- the nutrients administered include sugars, amino acids, electrolytes, and other nutrients needed for life support such as minerals and vitamins.
- the vitamin B1 solution is neutral and monobasic and unstable, and is decomposed by the presence of sulfite ions. Therefore, all of the above infusion preparations use an infusion containing a vitamin solution at a specific pH. In addition, vitamin B1 in infusion preparations is stabilized by adding no or minimum sulfite.
- Patent Document 1 JP-A-8-143459
- Patent Document 2 JP-A-9-59150
- Patent Document 3 JP-A-10-226636
- Patent document 4 JP-A-11-35471
- Patent Document 5 JP-A-2003-55195
- Non-patent Document 1 Nakamura et al., "Vitamin B1 Concentrations in Emergency Patients Undergoing Peripheral Parenteral Nutrition", Surgery and Metabolism ⁇ Nutrition, 36 (6), 307 (2002)
- An object of the present invention is to provide an infusion preparation for peripheral intravenous administration that further enhances the stability of vitamin B1 without impairing the safety and efficacy of the preparation, and a method of stabilizing vitamin B1.
- the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, have found that a salt having a buffering property mixed in an infusion solution stabilizes vitamin B1.
- a salt having a buffering property mixed in an infusion solution stabilizes vitamin B1.
- the infusion preparation for peripheral venous administration of the present invention comprises an infusion (A) containing glucose at a concentration of 80 to 200 g / L, and an amino acid containing 50 amino acids in a container partitioned by a partitioning means capable of communicating.
- the infusion solution (B) containing 150 g / L is separated and contained; the infusion solution (A) does not contain sulfite, has a titratable acidity of 1 or less, further contains vitamin B1, and has a pH of 3-5. It is adjusted; the infusion (B) is P H6 is adjusted to 5 8; is the infusion (a) and the infusion (B) 6 pH after mixing and the 7.5, titratable acidity 5 10. It is characterized by the following.
- the concentration of the carboxylic acid and the salt thereof contained in the infusion (A) is preferably 0.5 mE qZL.
- the electrolyte composition of the infusion solution (A) in the present invention is as follows: K + : 10 20 mEqZL, Ca 2+ : 210 mEq / L, Mg 2+ : 210 mEq / L, CI ": 12—30 mEq / L, Zn: 2— 10 mmol / L
- the electrolyte composition of infusion (B) is Na + : 80-150 mEq / L, K + : 20-40 mEq / L, P: 10-20 mmol / L, and the volume ratio of infusion (A) and infusion (B) (A: B) Force 11: 4: 1 is good.
- calcium and potassium are respectively compounded in the form of chlorides as the strong electrolyte, and sodium salt is used as a sodium supply source in the infusions (A) and (B). Is used, it is, it is preferred,
- the container is preferably a flexible plastic infusion bag having at least two chambers divided by an easily peelable seal.
- the method for stabilizing vitamin B1 of the present invention provides an infusion solution (A) containing vitamin B1 and 80-200 g / L glucose in a container partitioned by a partitioning means capable of communicating with the container. containing L amino acid P H6. 5 8 and adjusted infusion (B) is separated housed in a pH of 6 7.5 after mixing the transportation liquid (a) and the infusion (B),
- the infusion preparation for peripheral intravenous administration which has a titrated acidity of 5 10
- the infusion (A) does not contain sulfite
- the titration acidity of the infusion (A) is 1 or less
- the pH is 3-5. It is characterized by adjusting to.
- the concentration of the carboxylic acid and the salt thereof contained in the infusion (A) is preferably set to 0 to 5 mEq / L, and further, all the electrolyte contained in the infusion (A) is strongly electrolyzed. Good quality.
- the infusion preparation for peripheral intravenous administration of the present invention has the effect of further improving the stability of vitamin B1 without impairing the safety and efficacy.
- the infusion preparation of the present invention is one in which an infusion solution containing budose sugar (A) and an infusion solution containing amino acid (B) are separately contained in a container partitioned by a partitioning means capable of communicating.
- both infusions (A) and (B) are used as a mixture.
- the infusion (A) is based on glucose, a strong electrolyte and vitamin B1.
- the glucose solution is adjusted to a pH with a mineral acid such as hydrochloric acid in order to reduce the buffering property as much as possible, and furthermore, it is preferable that all the contained electrolytes are strong electrolytes.
- the pH of the infusion (A) is in the range of 35, preferably 3.5-4.5. When the pH is less than 3, the stability of vitamin B1 itself is excellent, but glucose becomes unstable. On the other hand, if the pH exceeds 5, the stability of vitamin B1 is impaired.
- the amount of glucose solution is preferably 200 lOOmL.
- distilled water for injection is usually used.
- the titratable acidity of the glucose solution is 1 or less, preferably 0.5 or less. , More preferably 0.1 or less.
- one or more reducing sugars such as fructose and maltose, or a non-reducing sugar such as sorbitol and glycerin may be added in an appropriate amount.
- the infusion solution is an amino acid solution containing an amino acid composition comprising at least essential amino acids.
- Amino acids are contained at a concentration of 50-150 g / L, preferably 80-120 g / L, in terms of free amino acids.
- Each amino acid used is preferably a pure crystalline amino acid, as in a general amino acid infusion. These are usually used in the form of a free amino acid, but need not be in the free form.
- pharmacologically acceptable salts, esters, N-acyl derivatives, salts of two kinds of amino acids, and peptides It can also be used in form.
- L-cysteine is preferably blended in the N-acetyl form in terms of stability.
- the amount of the infusion (B) to be stored in the infusion container is preferably 100 to 500 mL.
- distilled water for injection is usually used.
- the preferred amino acid composition is, in terms of free amino acid, L-leucine: 10-20 (g / L), L-isoleucine: 5-15 (g / L), L-valine: 515 (g / L) , L-lysine: 5 15 (g / L), L-threonine: 2-10 (g / L), L-tryptophan: 0.55 (g / L), L-methionine: 18 (g / L) L) ,: L—Fenilalanine: 3—15 (g / U ,: L—Cistine: 0.1-3 (g / L), L—Tyrosine: 0 ⁇ 1-2— (g / L), L—Arginine: 5—15 (g / L), L—Histidine: 2—10 (g / L), L—Alanine: 5—15 (g / L), L-proline: 2-10 (g / L), L_serine: 17 (g / L), glycine:
- Infusion (B) is adjusted to pH 6.5-8.0, preferably 6.7-7.5, by adding a small amount of a pH adjuster as needed. If the pH is less than 6.5, the pH after mixing cannot be maintained in the optimum range described later, while if it exceeds 8.0, L-cysteine and other oxidizable substances and amino acids become more unstable. , ⁇ , the deviation is also preferable.
- Vitamin B1 is preferably contained in the infusion (A) as a thiamine at a concentration of 110 mg / L, preferably 2-5 mg / L, and it is preferable to contain 0.58 mg as an absolute amount.
- thiamine thiamine hydrochloride, thiamine nitrate, prosultiamine, otatothiamine and the like can be used.
- potassium is separately added to the infusion (A) and the infusion (B). It is preferable that the concentration of each of the rhodium blends is 10 to 20 mEq / L for infusion (A) and 20 to 40 mEq / L for infusion). This potassium is preferably added to the infusion (A) and the infusion (B) in a total amount of 5 to 30 mEq.
- the potassium supply source to be mixed with the infusion (A) is preferably a strong electrolyte such as potassium chloride or potassium sulfate, and more preferably potassium chloride is widely used because it is widely used.
- the potassium supply source to be added to the infusion (B) the same compounds as those used for general electrolyte infusion and the like can be used, for example, potassium chloride, potassium acetate, potassium citrate, potassium dihydrogen phosphate. , Dipotassium hydrogen phosphate, potassium glycerate phosphate, potassium sulfate, potassium lactate, and the like.
- phosphates such as potassium dihydrogen phosphate, dipotassium hydrogen phosphate, and potassium glycerate are preferred because they also serve as a phosphorus supply source.
- These potassium sources may be in hydrate form.
- Sodium can be included in one or both of the infusion (A) and the infusion (B), but the use of chloride for potassium and calcium is preferred, so the power of not using sodium chloride as a sodium source is It is also preferable to prevent the occurrence of hyperchloric acidosis.
- the titration acidity of the infusion solution (A) described above is used. In order to satisfy the above condition, it is preferable to add it to the infusion solution. Further, the compounding concentration in the infusion) is preferably 80 to 150 mEq / L.
- magnesium source examples include magnesium sulfate, magnesium chloride, magnesium acetate and the like. Among them, magnesium sulfate and magnesium chloride can be blended as a strong electrolyte in the infusion (A).
- Examples of the phosphorus supply source include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, dibasic potassium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium glycerate phosphate and the like. . These phosphorus conjugates are blended into the infusion (B).
- Examples of the zinc supply source include zinc sulfate and zinc chloride. These zinc compounds can be incorporated into the infusion (A).
- a hydrate may be used as a source of each of these (i)-(iii) electrolytes.
- a buffering electrolyte must be added to the infusion (B).
- the concentration of each electrolyte was about 2-10 mEqZL for magnesium and about 2 lOmmolZL for zinc in the infusion (A). It is preferred that In addition, it is preferable that about 10 to 20 mmol / L of phosphorus is mixed in the infusion.
- Additives such as stabilizers can be added to the infusion preparation of the present invention as needed.
- Sulfites such as sodium bisulfite, which are typical stabilizers, are added to infusion (B). It is preferred to do so.
- the infusion preparation of the present invention may optionally contain other compounding agents, for example, various vitamins, trace elements (minerals), and the like.
- the infusion preparation of the present invention mixes the infusion (A) and the infusion (B) at the time of use.
- the mixture is preferably adjusted to have a pH in the range of 67.5 and a titratable acidity in the range of 510 in order to prevent the patient from causing vascular pain and to enhance the safety.
- the volume ratio of the infusion (A) to the infusion (B) is preferably 114: 4.
- the container for accommodating the infusion preparation of the present invention is not particularly limited as long as it has two chambers which can communicate with each other.
- a container in which a partition is formed by an easily peelable seal Japanese Patent Application Laid-Open No. 2-4671; 5-5138, etc.
- those in which a partition is formed by sandwiching between rooms with clips JP-A-63-309263, etc.
- various communication means that can be opened are provided in the partition
- a two-chamber container (infusion bag) separated by a communicable partition as in Japanese Patent Publication No. 63-20550.
- an infusion bag in which a partition wall is formed by an easily peelable seal is preferable because it is suitable for mass production and communication work is easy.
- Examples of the material of the infusion bag include various gas-permeable plastics commonly used for medical containers and the like, for example, polyethylene, polypropylene, polychlorinated vinyl, cross-linked ethylene. Flexible plastics such as horefin copolymers, blends of these polymers, and laminates.
- the infusion bag of the present invention can be filled and housed in an infusion bag in accordance with a conventional method.
- each solution is filled in each chamber under an inert gas atmosphere, and then sealed and heat sterilized.
- the heat sterilization is performed by a known method such as high-pressure steam sterilization and hot water shower sterilization. It can be employed, if necessary, in an atmosphere of an inert gas such as carbon dioxide or nitrogen.
- the infusion preparation contained in the above-mentioned infusion bag is preferably packaged in an oxygen-barrier outer bag together with a deoxidizer in order to surely prevent deterioration, oxidation and the like.
- the infusion bag is folded at an easily peelable seal portion so that the partition wall does not communicate with an external pressure, for example, easily peelable. It is preferable that the package is packaged in a state of being folded in two at the seal portion.
- inert gas filling packaging and the like can be performed as necessary.
- films and sheets of various materials generally used can be used as the material of the gas-impermeable outer container suitable for the packaging. Specific examples thereof include, for example, an ethylene-butyl alcohol copolymer, polyvinylidene chloride, polyacrylonitrile, polyvinyl alcohol, polyamide, polyester, and the like, or a film or sheet made of a material containing at least one of these.
- oxygen scavenger various known oxygen scavengers, for example, those containing an iron compound such as iron hydroxide, iron oxide or iron carbide as an active ingredient, or those using low molecular phenol and activated carbon can be used. Can use S power.
- the representative commercial names of these products are “Ageless” (Mitsubishi Gas Chemical), “Modulin” (Nippon Kayaku), “Sekiyur” (Nippon Soda), and “Tamotsu”.
- Glucose and each strong electrolyte were dissolved in distilled water for injection at the following concentrations to prepare an infusion (A) having the following composition.
- This infusion (A) was adjusted to pH 4.5 by adding a small amount of hydrochloric acid.
- the titration acidity of the infusion (A) was 0.08.
- the two solutions obtained above are aseptically filtered, and 700 mL of the infusion solution (A) and 300 mL of the infusion solution (B) are filled into each of the two polyethylene chambers, each of which is separated by an easily peelable seal.
- the atmosphere was replaced with nitrogen, sealed, and then subjected to high-pressure steam sterilization according to a conventional method.
- the container is folded at the easily peelable seal portion, and an outer bag (oxygen barrier property) of a multilayer barrier film (trade name “Boblon”; NSR) together with an oxygen absorber (trade name “Ageless”; manufactured by Mitsubishi Gas Chemical Company) (Outer bag) to obtain an infusion preparation of the present invention.
- an outer bag oxygen barrier property of a multilayer barrier film (trade name “Boblon”; NSR) together with an oxygen absorber (trade name “Ageless”; manufactured by Mitsubishi Gas Chemical Company) (Outer bag) to obtain an infusion preparation of the present invention.
- the mixed solution obtained by mixing the two solutions of this infusion preparation had a pH of 6.7 and a titratable acidity of 7.
- Example 1 An infusion preparation was obtained in the same manner as in Example 1, except that the pH of the infusion solution (A) in Example 1 was adjusted to 4.5 using acetic acid instead of hydrochloric acid.
- the titration acidity of the infusion (A) was 0.1 and the acetic acid concentration was 0.2 mEqZL. Further, the mixed solution after mixing the two solutions had a pH of 6.7 and a titratable acidity of 7.
- An infusion preparation was obtained in the same manner as in Example 1, except that potassium dihydrogen phosphate (1.68 g / L) was added instead of potassium chloride in infusion (A) of Example 1.
- the titration acidity of the infusion (A) was 1.
- the mixed solution after mixing the two solutions had a pH of 6.7 and a titration acidity of 7.
- Example 1 In the infusion (A) of Example 1, instead of calcium chloride (2H0) 0.53 g ZL, 1.6 g / L of calcium dalconate was added, and the infusion (B) was added with sodium lactate 7.63 g / L. An infusion preparation was obtained in the same manner as in Example 1 except that instead of adding L, 3.27 gZL of sodium lactate was added to the infusion (A). The titration acidity of the infusion (A) was 4.9.
- Example 2 An infusion preparation was obtained in the same manner as in Example 2, except that 0.77 g ZL of magnesium acetate (4H0) was added in place of magnesium sulfate (7H) in Infusion (A) of Example 2.
- the titration acidity of the infusion (A) was 1.6 and the acetic acid concentration was 8.5 mEq / L. Further, the mixed solution after mixing the two solutions had a pH of 6.6 and a titratable acidity of 8.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005506329A JP4594232B2 (ja) | 2003-05-22 | 2004-05-14 | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 |
DE602004014760T DE602004014760D1 (de) | 2003-05-22 | 2004-05-14 | Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1 |
US10/556,772 US20060211631A1 (en) | 2003-05-22 | 2004-05-14 | Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1 |
CA2526208A CA2526208C (en) | 2003-05-22 | 2004-05-14 | Infusion preparation for peripheral parenteral administration and method for stabilizing vitamin b1 |
AU2004241840A AU2004241840B2 (en) | 2003-05-22 | 2004-05-14 | Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin B1 |
EP04733089A EP1632233B1 (en) | 2003-05-22 | 2004-05-14 | Transfusion preparation for peripheral intravenous administration and method of stabilizing vitamin b1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-145353 | 2003-05-22 | ||
JP2003145353 | 2003-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004103375A1 true WO2004103375A1 (ja) | 2004-12-02 |
Family
ID=33475233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006539 WO2004103375A1 (ja) | 2003-05-22 | 2004-05-14 | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060211631A1 (ja) |
EP (1) | EP1632233B1 (ja) |
JP (1) | JP4594232B2 (ja) |
KR (1) | KR101039224B1 (ja) |
CN (1) | CN100486579C (ja) |
AT (1) | ATE399556T1 (ja) |
AU (1) | AU2004241840B2 (ja) |
CA (1) | CA2526208C (ja) |
DE (1) | DE602004014760D1 (ja) |
TW (1) | TWI331043B (ja) |
WO (1) | WO2004103375A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006137745A (ja) * | 2004-10-15 | 2006-06-01 | Nipro Corp | ビタミンb群配合末梢静脈栄養輸液 |
WO2008146732A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液 |
WO2008146731A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液の製造方法 |
JP2009506030A (ja) * | 2005-08-24 | 2009-02-12 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | アセチルシステイン組成物及びその使用 |
JPWO2007055312A1 (ja) * | 2005-11-10 | 2009-04-30 | 田辺三菱製薬株式会社 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
WO2010104023A1 (ja) * | 2009-03-11 | 2010-09-16 | 味の素株式会社 | ビタミンb1を安定に配合した糖液を含む末梢静脈投与用輸液 |
JP2017014287A (ja) * | 2010-05-07 | 2017-01-19 | エイワイファーマ株式会社 | 高圧蒸気滅菌済み静脈投与用栄養輸液の安定化方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI319984B (en) * | 2003-06-06 | 2010-02-01 | Sterile combined preparation | |
JP5554466B2 (ja) * | 2004-03-01 | 2014-07-23 | 味の素株式会社 | 抗ヒトTNF−α抗体活性低下抑制剤 |
AU2011202871B2 (en) * | 2005-08-24 | 2014-06-12 | Cumberland Pharmaceuticals Inc. | Acetylcysteine composition and uses therefor |
AU2013207545B2 (en) * | 2008-07-07 | 2015-06-18 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
GB2494234B (en) * | 2008-07-07 | 2013-08-07 | Pentec Health Inc | Nutritive compositions and methods of using same |
NZ601027A (en) * | 2010-01-04 | 2014-08-29 | Pentec Health Inc | Nutritive compositions and methods of using same |
SG190915A1 (en) | 2010-11-29 | 2013-07-31 | Otsuka Pharma Co Ltd | Infusion preparation |
CN105412896B (zh) * | 2016-01-06 | 2021-08-31 | 鲁南制药集团股份有限公司 | 一种避免安神补脑液中维生素b1含量下降的方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0328403B2 (ja) * | 1982-07-16 | 1991-04-19 | Eezai Kk | |
JPH06312923A (ja) * | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | 末梢静脈投与用栄養輸液 |
JPH08143459A (ja) * | 1994-11-17 | 1996-06-04 | Tanabe Seiyaku Co Ltd | 水溶性ビタミンb類配合総合輸液 |
JPH0959150A (ja) * | 1995-08-11 | 1997-03-04 | Roussel Morishita Kk | 経静脈用輸液製剤 |
JPH1087497A (ja) * | 1996-09-17 | 1998-04-07 | Otsuka Pharmaceut Factory Inc | 末梢静脈投与用輸液 |
JPH1087498A (ja) * | 1996-09-17 | 1998-04-07 | Otsuka Pharmaceut Factory Inc | 中心静脈投与用輸液 |
JPH1135471A (ja) * | 1997-07-18 | 1999-02-09 | Hoechst Marion Roussel Kk | 2室容器入りビタミンb1配合栄養輸液剤 |
JP2003055195A (ja) * | 2001-08-20 | 2003-02-26 | Terumo Corp | ビタミンb1配合末梢静脈投与用総合輸液剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4162306B2 (ja) * | 1997-09-25 | 2008-10-08 | 株式会社大塚製薬工場 | 中心静脈投与用輸液 |
TW367247B (en) * | 1998-02-03 | 1999-08-21 | Otsuka Pharma Co Ltd | Storage container for Vitamin D solution and transfusion container |
JP4767375B2 (ja) * | 1999-03-19 | 2011-09-07 | 田辺三菱製薬株式会社 | 総合輸液剤 |
JP4101418B2 (ja) * | 1999-12-03 | 2008-06-18 | 田辺三菱製薬株式会社 | 総合栄養輸液剤 |
US6391332B1 (en) * | 2000-04-20 | 2002-05-21 | Baxter International, Inc. | Therapeutic micronutrient composition for severe trauma, burns and critical illness |
JP2006001945A (ja) * | 2005-09-01 | 2006-01-05 | Terumo Corp | ビタミンb1配合末梢静脈投与用総合輸液剤 |
-
2004
- 2004-05-14 EP EP04733089A patent/EP1632233B1/en not_active Expired - Lifetime
- 2004-05-14 CN CNB2004800105385A patent/CN100486579C/zh not_active Expired - Lifetime
- 2004-05-14 WO PCT/JP2004/006539 patent/WO2004103375A1/ja active IP Right Grant
- 2004-05-14 AT AT04733089T patent/ATE399556T1/de not_active IP Right Cessation
- 2004-05-14 CA CA2526208A patent/CA2526208C/en not_active Expired - Lifetime
- 2004-05-14 AU AU2004241840A patent/AU2004241840B2/en not_active Expired
- 2004-05-14 DE DE602004014760T patent/DE602004014760D1/de not_active Expired - Lifetime
- 2004-05-14 KR KR1020057021088A patent/KR101039224B1/ko active IP Right Grant
- 2004-05-14 US US10/556,772 patent/US20060211631A1/en not_active Abandoned
- 2004-05-14 JP JP2005506329A patent/JP4594232B2/ja not_active Expired - Lifetime
- 2004-05-21 TW TW093114411A patent/TWI331043B/zh active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0328403B2 (ja) * | 1982-07-16 | 1991-04-19 | Eezai Kk | |
JPH06312923A (ja) * | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | 末梢静脈投与用栄養輸液 |
JPH08143459A (ja) * | 1994-11-17 | 1996-06-04 | Tanabe Seiyaku Co Ltd | 水溶性ビタミンb類配合総合輸液 |
JPH0959150A (ja) * | 1995-08-11 | 1997-03-04 | Roussel Morishita Kk | 経静脈用輸液製剤 |
JPH1087497A (ja) * | 1996-09-17 | 1998-04-07 | Otsuka Pharmaceut Factory Inc | 末梢静脈投与用輸液 |
JPH1087498A (ja) * | 1996-09-17 | 1998-04-07 | Otsuka Pharmaceut Factory Inc | 中心静脈投与用輸液 |
JPH1135471A (ja) * | 1997-07-18 | 1999-02-09 | Hoechst Marion Roussel Kk | 2室容器入りビタミンb1配合栄養輸液剤 |
JP2003055195A (ja) * | 2001-08-20 | 2003-02-26 | Terumo Corp | ビタミンb1配合末梢静脈投与用総合輸液剤 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006137745A (ja) * | 2004-10-15 | 2006-06-01 | Nipro Corp | ビタミンb群配合末梢静脈栄養輸液 |
JP2009506030A (ja) * | 2005-08-24 | 2009-02-12 | カンバーランド ファーマシューティカルズ,インコーポレーテッド | アセチルシステイン組成物及びその使用 |
JPWO2007055312A1 (ja) * | 2005-11-10 | 2009-04-30 | 田辺三菱製薬株式会社 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
JP5973118B2 (ja) * | 2005-11-10 | 2016-08-23 | 田辺三菱製薬株式会社 | ピラゾロン化合物含有水溶液が充填されたプラスチック容器 |
WO2008146732A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液 |
WO2008146731A1 (ja) * | 2007-05-25 | 2008-12-04 | Ajinomoto Co., Inc. | 末梢静脈投与用輸液の製造方法 |
JPWO2008146732A1 (ja) * | 2007-05-25 | 2010-08-19 | 味の素株式会社 | 末梢静脈投与用輸液 |
WO2010104023A1 (ja) * | 2009-03-11 | 2010-09-16 | 味の素株式会社 | ビタミンb1を安定に配合した糖液を含む末梢静脈投与用輸液 |
JP2017014287A (ja) * | 2010-05-07 | 2017-01-19 | エイワイファーマ株式会社 | 高圧蒸気滅菌済み静脈投与用栄養輸液の安定化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100486579C (zh) | 2009-05-13 |
EP1632233B1 (en) | 2008-07-02 |
AU2004241840B2 (en) | 2010-02-25 |
CA2526208A1 (en) | 2004-12-02 |
US20060211631A1 (en) | 2006-09-21 |
TW200501931A (en) | 2005-01-16 |
EP1632233A1 (en) | 2006-03-08 |
AU2004241840A1 (en) | 2004-12-02 |
KR101039224B1 (ko) | 2011-06-03 |
KR20060015584A (ko) | 2006-02-17 |
JPWO2004103375A1 (ja) | 2006-07-20 |
CA2526208C (en) | 2011-11-08 |
CN1777428A (zh) | 2006-05-24 |
TWI331043B (en) | 2010-10-01 |
ATE399556T1 (de) | 2008-07-15 |
DE602004014760D1 (de) | 2008-08-14 |
JP4594232B2 (ja) | 2010-12-08 |
EP1632233A4 (en) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004103375A1 (ja) | 末梢静脈投与用輸液製剤およびビタミンb1の安定化方法 | |
TWI474840B (zh) | 綜合營養輸液劑 | |
CN105342995B (zh) | 输液制剂 | |
AU737855B2 (en) | Vitamin D solution holder and containers for transfusions | |
JP4162306B2 (ja) | 中心静脈投与用輸液 | |
EP1632209A1 (en) | Aseptic combination preparation | |
JPWO2008146732A1 (ja) | 末梢静脈投与用輸液 | |
JP5552763B2 (ja) | 末梢静脈投与用輸液製剤 | |
JP3771644B2 (ja) | 末梢静脈投与用輸液 | |
JP4956935B2 (ja) | 輸液製剤 | |
JP4142282B2 (ja) | 微量金属を含む輸液製剤 | |
JP3824716B2 (ja) | 中心静脈投与用輸液 | |
JP2005179200A (ja) | ビタミンb1類配合輸液剤 | |
JP2004001900A (ja) | 中心静脈投与用輸液中のビタミン類の安定化方法 | |
JP2004189677A (ja) | 輸液製剤 | |
JP2003055195A (ja) | ビタミンb1配合末梢静脈投与用総合輸液剤 | |
JP2006001945A (ja) | ビタミンb1配合末梢静脈投与用総合輸液剤 | |
JP4178563B2 (ja) | 2室容器入りビタミンb1配合栄養輸液剤 | |
JPH10203959A (ja) | 中心静脈投与用輸液 | |
JP2008195737A (ja) | 微量金属を含む輸液製剤 | |
JP2006104077A (ja) | 末梢静脈栄養輸液製剤 | |
JP6014861B2 (ja) | 末梢静脈投与用輸液製剤 | |
JP2010090039A (ja) | 還元糖とアミノ酸を含む一液化末梢静脈投与用輸液製剤 | |
JP2003212767A (ja) | 含硫化合物と微量金属元素を含む輸液製剤 | |
JP2005220105A (ja) | 末梢静脈栄養輸液製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20048105385 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057021088 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10556772 Country of ref document: US Ref document number: 2005506329 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2526208 Country of ref document: CA Ref document number: 2004241840 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004733089 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004241840 Country of ref document: AU Date of ref document: 20040514 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004241840 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057021088 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004733089 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10556772 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004733089 Country of ref document: EP |